Men (n = 18,882) over the age of 55 without evidence of prostate cancer detected by digital rectal exam (DRE) or prostate-specific antigen (PSA) levels were randomized to receive either 5 mg/day finasteride or placebo for 7 years. Here, KLK3 is linked to prostate carcinoma.